Aerosol delivery of stabilized polyester-siRNA nanoparticles to silence gene expression in orthotopic lung tumors

详细信息    查看全文

• 作者：Yunfeng Yan^a ; ^b ; Kejin Zhou^a ; ^b ; Hu Xiong^a ; ^b ; Jason B. Miller^a ; ^b ; Edward A. Motea^a ; ^c ; ^d ; David A. Boothman^a ; ^c ; ^d ; Li Liu^e ; ^{Li.Liu@UTSouthwestern.edu} ; Daniel J. Siegwart^a ; ^b ; ^{Daniel.Siegwart@UTSouthwestern.edu}
• 关键词：Functional polyesters ; siRNA ; Cancer ; Drug delivery ; Nanoparticles
• 刊名：Biomaterials
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：118
• 期：Complete
• 页码：84-93
• 全文大小：2459 K
• 卷排序：118

文摘

Tremendous progress has been made in the development of delivery carriers for small RNA therapeutics. However, most achievements have focused on the treatment of liver-associated diseases because conventional lipid and lipidoid nanoparticles (LNPs) readily accumulate in the liver after intravenous (i.v.) administration. Delivering RNAs to other organs and tumor tissues remains an ongoing challenge. Here, we utilized a 540-member combinatorial functional polyester library to discover nanoparticles (NPs) that enable efficacious siRNA delivery to A549 lung cancer cells in vitro and in vivo. PE4K-A13–0.33C6 and PE4K-A13–0.33C10 NPs were efficiently internalized into A549-Luc cells within 4 h. The addition of PEG 2000 DMG lipid or Pluronic F-127 onto the surface of the polyplexes reduced the surface charge of NPs, resulting in an increase of serum stability. We then explored aerosol delivery of stabilized PE4K-A13–0.33C6 and PE4K-A13–0.33C10 NPs to implanted orthotopic lung tumors. We found that by altering the administration route from i.v. to aerosol, the NPs could avoid liver accumulation and instead be specifically localized only in the lungs. This resulted in significant gene silencing in the A549 orthotopic lung tumors. Due to the ability to deliver siRNA to non-liver targets, this approach provides a privileged route for gene silencing in the lungs.